E3 ligase Ligand 10

 CAS No.: 1073560-68-5  Cat No.: BP-200010 4.5  

E3 Ligase Ligand 10 is a high-affinity small molecule specifically designed for the construction of PROTAC (Proteolysis Targeting Chimera) compounds and molecular glue degraders. Functioning as an E3 ligase recruiter, this ligand facilitates the targeted ubiquitination and subsequent degradation of disease-related proteins by linking an E3 ubiquitin ligase to the protein of interest. Classified as an "E3 Ligase Ligand," it is a crucial component in targeted protein degradation workflows. E3 Ligase Ligand 10 allows researchers to exploit the protein degradation pathway, enabling the development of novel therapeutic strategies against previously undruggable targets. Its versatility ensures broad compatibility with various linker systems for the generation of custom PROTACs, providing an essential tool for hit identification, SAR studies, and preclinical drug discovery in oncology, neurodegenerative disorders, and other therapeutic fields.

E3 ligase Ligand 10

Structure of 1073560-68-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Ligand for E3 Ligase
Molecular Formula
C47H52N4O7
Molecular Weight
784.94

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Solubility
10 mM in DMSO
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping
Room temperature in continental US; may vary elsewhere
Synonyms
(2S)-2-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3,3-diphenylpropanoic acid
InChI Key
GZMLKDJDSMXRGP-HCVICXAGSA-N
InChI
InChI=1S/C47H52N4O7/c1-30(50(2)47(57)58-29-38-36-25-14-12-23-34(36)35-24-13-15-26-37(35)38)43(52)48-41(33-21-10-5-11-22-33)45(54)51-28-16-27-39(51)44(53)49-42(46(55)56)40(31-17-6-3-7-18-31)32-19-8-4-9-20-32/h3-4,6-9,12-15,17-20,23-26,30,33,38-42H,5,10-11,16,21-22,27-29H2,1-2H3,(H,48,52)(H,49,53)(H,55,56)/t30-,39-,41-,42-/m0/s1
Canonical SMILES
CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C(=O)NC(C(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O)N(C)C(=O)OCC5C6=CC=CC=C6C7=CC=CC=C57

Background Introduction

E3 ligase Ligand 10 is a novel small molecule designed to selectively bind to a specific E3 ubiquitin ligase, facilitating its incorporation in targeted protein degradation strategies such as PROTAC (Proteolysis Targeting Chimera) technology. E3 ubiquitin ligases play a crucial role in protein homeostasis by tagging proteins with ubiquitin, leading to their proteasomal degradation. Synthetic E3 ligase ligands like E3 ligase Ligand 10 provide researchers with essential tools to expand the repertoire of targetable proteins and explore new E3 ligase possibilities beyond traditional ligands such as CRBN and VHL.

Mechanism

E3 ligase Ligand 10 functions as a recruiting element by binding to its cognate E3 ubiquitin ligase and tethering it to a specific target protein via a bifunctional PROTAC molecule. When E3 ligase Ligand 10 is conjugated to a suitable ligand for the protein of interest through a linker, the resulting PROTAC brings the target protein in proximity to the E3 ligase. This induced proximity promotes ubiquitin transfer to the target protein, ultimately marking it for recognition and breakdown by the 26S proteasome. As a result, unwanted or disease-related proteins can be selectively and efficiently degraded within cells.

Applications

E3 ligase Ligand 10 is an advanced tool for researchers aiming to develop next-generation degraders for therapeutic discovery and mechanistic biology. Its unique E3 ligase specificity broadens the scope of protein degradation, especially for targets that are less responsive to traditional ligase ligands. Applications include:

• Design and synthesis of novel PROTACs targeting previously undruggable proteins.
• Expanding E3 ligase toolbox in targeted protein degradation for both drug development and basic research.
• Development of molecular glues for modulating protein-protein interactions via E3 ligase recruitment.
• Structure-activity relationship (SAR) studies and optimization of degrader molecules.
• Custom synthesis for contract research organizations (CROs), biotechnology firms, and academic labs exploring new E3 ligase systems.
• High-purity compound verified by HPLC, NMR, and LC-MS
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• High selectivity for E3 ligase recruitment, enabling targeted protein degradation applications in PROTAC research.
• Optimized chemical structure ensures reliable performance and compatibility in a wide range of custom PROTAC designs.
1. TGF-β Signaling
Kalliopi Tzavlaki, Aristidis Moustakas Biomolecules. 2020 Mar 23;10(3):487.doi: 10.3390/biom10030487.
Transforming growth factor-β (TGF-β) represents an evolutionarily conserved family of secreted polypeptide factors that regulate many aspects of physiological embryogenesis and adult tissue homeostasis. The TGF-β family members are also involved in pathophysiological mechanisms that underlie many diseases. Although the family comprises many factors, which exhibit cell type-specific and developmental stage-dependent biological actions, they all signal via conserved signaling pathways. The signaling mechanisms of the TGF-β family are controlled at the extracellular level, where ligand secretion, deposition to the extracellular matrix and activation prior to signaling play important roles. At the plasma membrane level, TGF-βs associate with receptor kinases that mediate phosphorylation-dependent signaling to downstream mediators, mainly the SMAD proteins, and mediate oligomerization-dependent signaling to ubiquitin ligases and intracellular protein kinases. The interplay between SMADs and other signaling proteins mediate regulatory signals that control expression of target genes, RNA processing at multiple levels, mRNA translation and nuclear or cytoplasmic protein regulation. This article emphasizes signaling mechanisms and the importance of biochemical control in executing biological functions by the prototype member of the family, TGF-β.
2. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors
Martin Selinger, Pavlína Věchtová, Hana Tykalová, Petra Ošlejšková, Michaela Rumlová, Ján Štěrba, Libor Grubhoffer Comput Struct Biotechnol J. 2022 May 30;20:2759-2777.doi: 10.1016/j.csbj.2022.05.052.eCollection 2022.
Tick-borne encephalitis virus (TBEV), the most medically relevant tick-transmitted flavivirus in Eurasia, targets the host central nervous system and frequently causes severe encephalitis. The severity of TBEV-induced neuropathogenesis is highly cell-type specific and the exact mechanism responsible for such differences has not been fully described yet. Thus, we performed a comprehensive analysis of alterations in host poly-(A)/miRNA/lncRNA expression upon TBEV infection in vitro in human primary neurons (high cytopathic effect) and astrocytes (low cytopathic effect). Infection with severe but not mild TBEV strain resulted in a high neuronal death rate. In comparison, infection with either of TBEV strains in human astrocytes did not. Differential expression and splicing analyses with an in silico prediction of miRNA/mRNA/lncRNA/vd-sRNA networks found significant changes in inflammatory and immune response pathways, nervous system development and regulation of mitosis in TBEV Hypr-infected neurons. Candidate mechanisms responsible for the aforementioned phenomena include specific regulation of host mRNA levels via differentially expressed miRNAs/lncRNAs or vd-sRNAs mimicking endogenous miRNAs and virus-driven modulation of host pre-mRNA splicing. We suggest that these factors are responsible for the observed differences in the virulence manifestation of both TBEV strains in different cell lines. This work brings the first complex overview of alterations in the transcriptome of human astrocytes and neurons during the infection by two TBEV strains of different virulence. The resulting data could serve as a starting point for further studies dealing with the mechanism of TBEV-host interactions and the related processes of TBEV pathogenesis.
3. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment
Jinghui Zhang, Jiajun Fan, Xian Zeng, Mingming Nie, Jingyun Luan, Yichen Wang, Dianwen Ju, Kai Yin Acta Pharm Sin B. 2021 Mar;11(3):609-620.doi: 10.1016/j.apsb.2020.10.022.Epub 2020 Oct 29.
The Hedgehog (HH) signaling pathway plays important roles in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment (TME). Aberrant HH signaling activation may accelerate the growth of gastrointestinal tumors and lead to tumor immune tolerance and drug resistance. The interaction between HH signaling and the TME is intimately involved in these processes, for example, tumor growth, tumor immune tolerance, inflammation, and drug resistance. Evidence indicates that inflammatory factors in the TME, such as interleukin 6 (IL-6) and interferon-γ (IFN-γ), macrophages, and T cell-dependent immune responses, play a vital role in tumor growth by affecting the HH signaling pathway. Moreover, inhibition of proliferating cancer-associated fibroblasts (CAFs) and inflammatory factors can normalize the TME by suppressing HH signaling. Furthermore, aberrant HH signaling activation is favorable to both the proliferation of cancer stem cells (CSCs) and the drug resistance of gastrointestinal tumors. This review discusses the current understanding of the role and mechanism of aberrant HH signaling activation in gastrointestinal carcinogenesis, the gastrointestinal TME, tumor immune tolerance and drug resistance and highlights the underlying therapeutic opportunities.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Inquiry Basket